Ashenden Stephanie K, Kogej Thierry, Engkvist Ola, Bender Andreas
Centre for Molecular Informatics, Department of Chemistry, University of Cambridge , Cambridge, CB2 1EW, United Kingdom.
Discovery Sciences, IMED Biotech Unit, AstraZeneca , Gothenburg 431 50 SE, Sweden.
J Chem Inf Model. 2017 Nov 27;57(11):2741-2753. doi: 10.1021/acs.jcim.7b00295. Epub 2017 Nov 14.
It is well-established that the number of publications of novel small molecule modulators, and their associated targets, has increased over the years. This work focuses on publishing trends over the years with a particular focus on the comparison between patents and scientific literature which is accessible via the ChEMBL and GOSTAR databases. More precisely, the patents and scientific literature associated with bioactive molecules and their target annotations have been compared to identify where novelty (in the meaning of the first modulator of a protein target) originated from. Comparing the published date of the first small molecule modulator published in literature and patents for a particular target (with either identical or different structure) shows that modulators are usually published in both scientific literature and in patents (45%), or in scientific literature alone (51%), but rarely in patents only. When looking at the time when first modulators are published in both sources, 65% of the time they are disseminated in literature first. Finally, when analyzing just the novel small molecule modulators, regardless of the protein targets they have been published with, those structures representing novel chemistry tend to be published in patents first 61% of the time.
多年来,新型小分子调节剂及其相关靶点的出版物数量不断增加,这一点已得到充分证实。这项工作聚焦于多年来的出版趋势,尤其着重于通过ChEMBL和GOSTAR数据库可获取的专利与科学文献之间的比较。更确切地说,已对与生物活性分子及其靶点注释相关的专利和科学文献进行比较,以确定新颖性(蛋白质靶点的首个调节剂的意义)的来源。比较针对特定靶点(具有相同或不同结构)在文献和专利中发表的首个小分子调节剂的出版日期表明,调节剂通常在科学文献和专利中都有发表(45%),或者仅在科学文献中发表(51%),但很少仅在专利中发表。当查看首个调节剂在两种来源中发表的时间时,65%的情况下它们首先在文献中传播。最后,在仅分析新型小分子调节剂时,无论它们所发表的蛋白质靶点如何,那些代表新化学结构的调节剂有61%的情况倾向于首先在专利中发表。